Central Bank of Samoa Launches Regulatory SandboxNEW YORK--(BUSINESS WIRE)--Nov 24, 2024-- Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of AMMO, Inc. (NASDAQ: POWW) between August 19, 2020 and September 24, 2024. AMMO describes itself as a “company that designs, produces, and markets ammunition and ammunition component products for public consumers, manufacturers, and law enforcement and military agencies.” For more information, submit a form , email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that AMMO, Inc. (NASDAQ: POWW) Misled Investors Regarding its Business Operations. According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AMMO lacked adequate internal controls over financial reporting; (2) there was a substantial likelihood AMMO failed to accurately disclose all executive officers, members of management, and potential related party transactions in fiscal years 2020 through 2023; (3) there was a substantial likelihood AMMO failed to properly characterize certain fees paid for investor relations and legal services as reductions of proceeds from capital raises rather than period expenses in fiscal years 2021 and 2022; (4) there was a substantial likelihood AMMO failed to appropriately value unrestricted stock awards to officers, directors, employees and others in fiscal years 2020 through 2022; and (5) as a result of the foregoing, defendants’ positive statements about AMMO’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against AMMO, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by November 29, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. View source version on businesswire.com : https://www.businesswire.com/news/home/20241124774051/en/ CONTACT: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com KEYWORD: NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Rosen Law Firm, P.A. Copyright Business Wire 2024. PUB: 11/24/2024 09:01 AM/DISC: 11/24/2024 09:01 AM http://www.businesswire.com/news/home/20241124774051/en
The Pittsburgh Steelers will look to move on from their upset loss against the Cleveland Browns in Week 12. One of the biggest moments from the game came in the fourth quarter on the Steelers' second-to-last drive, when they decided to put backup quarterback Justin Fields into the game on a third-and-six with the lead. Rather than using Fields to run the clock out with under four minutes remaining, Pittsburgh chose to take a deep shot to George Pickens that fell incomplete. Barry Reeger-Imagn Images After the play, the Steelers punted, and the Browns went down the field and scored the game-winning touchdown with under a minute remaining. On Tuesday, coach Mike Tomlin was asked about the controversial play call and defended the decision with an honest take. "We felt good about it, to be quite honest with you," said Tomlin. "It was a weighty moment. It was third-and-medium. They had 11 guys within five yards of the line of scrimmage. We had GP matched up on a corner not named Denzel Ward. That feels like more than a 50-50 ball to me, and so we were comfortable with that decision." Related: Steelers Look to Rebound in Crucial AFC North Matchup Obviously, if the play had been successful then the discussions surrounding it would be very different, but deciding to put Fields (whose speciality is running) in the game to make that play over Russell Wilson is still a confusing choice. Although the Steelers do still sit at first place in the AFC North after the loss, they're just a half-game ahead of the Baltimore Ravens for the top spot, meaning they have very little room for error in the coming weeks. Related: Steelers Face Power Rankings Following Loss
None
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . [You may also click here for additional information] NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) and reminds investors of the January 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that the Company's Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) that the FDA's review of the BLA would be delayed while Humacyte remediated these deficiencies; and (3) that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On August 9, 2024, after the market closed, Humacyte issued a press release announcing that the Food and Drug Administration ("FDA") "will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication." The press release disclosed in part, that, "[d]uring the course of the BLA review, the FDA has conducted inspections of our manufacturing facilities and clinical sites and has actively engaged with us in multiple discussions regarding our BLA filing[.]" On this news, the Company's stock price declined $1.29, or 16.4%, to close at $6.62 per share on August 12, 2024, on unusually heavy volume. On October 17, 2024, during market hours, the FDA released a Form 483 concerning Humacyte's Durham, North Carolina facility, which revealed a number of violations, including "no microbial quality assurance," "no microbial testing," and inadequate "quality oversight." On this news, the Company's stock price declined $0.95, or 16.35%, to close at $4.86 per share on October 17, 2024, on unusually heavy volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information Humacyte’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Humacyte class action, go to www.faruqilaw.com/HUMA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . Follow us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/807ffe71-382e-48fd-91d1-846d96405715"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" Thanks for your interest in Kalkine Media's content! To continue reading, please log in to your account or create your free account with us."Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" Thanks for your interest in Kalkine Media's content! To continue reading, please log in to your account or create your free account with us.
Purpose Investments Inc. Announces 2024 Final Annual Income and Capital Gains Distributions For Purpose Mutual Fund Trusts with December 15, 2024 Tax Year-End
Former World No. 1 Lleyton Hewitt made history during his debut at the 1997 Australian Open . Now, his 16-year-old son Cruz, who recently received a wildcard for the tournament's qualifying rounds, has the opportunity to replicate his father's achievement as the youngest player to reach the main draw at the first Grand Slam of the year. Not everyone was pleased with Cruz receiving the wildcard, as many fans on social media criticized the decision and accused the organisers of "nepotism." The Australian teenager, currently ranked No. 107 in the junior category and World No. 1264 in the ATP rankings, will be the lowest-ranked player in the qualifying rounds. Cruz Hewitt steps into the spotlight As the son of a two-time Grand Slam champion, Cruz faces high expectations to follow in his father's footsteps. Lleyton was not only one of the best players in tennis history but also shone at an early age. He remains the second-youngest player to achieve the World No. 1 ranking, a feat he accomplished at 20 years and 9 months, a record surpassed only by Carlos Alcaraz in 2022 at 19 years and 4 months. Lleyton still holds the record for the youngest player to reach the Australian Open main draw, a milestone he achieved in 1997 at just 15 years and 323 days. He lost in the first round to Sergi Bruguera in straight sets. Cruz will need to win three consecutive matches to qualify for the main draw, which would make him the youngest player to advance through the Australian Open qualifiers since his father in 1997. However, even if successful, Cruz would still fall short of his father's record, as he would enter the main draw at 16 years and 32 days old—just over two months older than Lleyton was when he set the record 27 years ago. Una publicación compartida por Tennis Australia (@tennisaustralia) This article first appeared on TennisUpToDate.com and was syndicated with permission.
Blake Lively is defended by director Paul Feig amid allegations of a smear campaign by Justin Baldoni Have YOU got a story? Email tips@dailymail.com By ALESIA STANFORD FOR DAILYMAIL.COM Published: 20:24 GMT, 23 December 2024 | Updated: 20:29 GMT, 23 December 2024 e-mail 60 shares 8 View comments Blake Lively has received support from a director who praised her work ethic in a social media post following her sexual harassment complaint against Justin Baldoni . Lively, 37, has accused It Ends With Us director and star of creating an 'hostile work environment' while working on the film and hiring a crisis management team to 'take down' the actress afterward. Paul Feig, 62, who worked with Lively on the psychological thriller A Simple Favor and the sequel, A Simple Favor 2, took to X/ Twitter on Sunday to defend her. 'I’ve now made two movies with Blake and all I can say is she’s one of the most professional, creative, collaborative, talented and kind people I’ve ever worked with,' the Directors Guild of America Award winner stated. 'She truly did not deserve any of this smear campaign against her. I think it’s awful she was put through this.' Feig included the link to an article in The New York Times detailing alleged efforts to make the veteran star look bad during the promotion of the drama about domestic violence after rumors of discord between her and Baldoni, 40, emerged. Director Paul Feig, 62, has offered his support to embattled actress Blake Lively, 37 amid her sexual harassment complaint against It Ends With Us director and star Justin Baldoni alleging he created a hostile work environment on set and launched a smear campaign against her The legal complaint , filed Friday, contained subpoenaed communication, including texts, between Baldoni and the PR Crisis team he hired. 'You know we can bury anyone, but I can't write that to him (Baldoni)' Melissa Nathan of The Agency Group wrote to Jennifer Abel of RWA communications in a text. Nathan reportedly represented Johnny Depp during his 2022 lawsuit against former wife Amber Heard, following an op-ed piece she wrote about her experience with domestic violence in The Washington Post . Heard did not mention the actor by name in the piece. A screen shot showing an unflattering article about Hailey Bieber being a bully alleged to be from Baldoni to Abel was included in the documents, with Baldoni telling his team 'this is what we would need.' Lively's breakout role was in 2005's The Sisterhood of the Traveling Pants and her co-stars, America Ferrera , Amber Tamblyn and Alexis Bledel, have all spoken in support of their longtime friend. In a joint Instagram post on Sunday, Tamblyn and Ferrera released a statement signed by all three of them, including Bledel, who is not active on the platform. 'In support of our sister, Blake,' they wrote in the caption and signed off with a red heart emoji and their first names. 'As Blake's friends and sisters for over twenty years, we stand with her in solidarity as she fights back against the reported campaign waged to destroy her reputation,' the trio's statement read. The director spoke out in a posting on X/Twitter Sunday night, praising the actress for her work ethic Feig worked with Lively on 2018's A Simple Favor and the upcoming sequel Lively has accused Baldoni, 40, of launching a smear campaign against her by hiring a PR Crisis management team to 'take' her 'down'. The actor and director has denied the allegations Read More Amber Heard speaks out about Blake Lively's Justin Baldoni claims as celebs pick sides in viral feud 'Throughout the filming of It Ends With Us, we saw her summon the courage to ask for a safe workplace for herself and colleagues on set,' they stated. 'And we are appalled to read the evidence of a premeditated and vindictive effort that ensued to discredit her voice,' they continued. 'Most upsetting is the unabashed exploitation of domestic violence survivors' stories to silence a woman who asked for safety,' Lively's Sisterhood co-stars wrote. 'The hypocrisy is astounding.' Lively's Sisterhood of the Traveling Pants co-stars have also come forward to defend Lively whom they have known for some two decades: from left to right: Lively, Ferrera, Bledel, Tamblyn pictured in 2008 portrait The three actresses issued a lengthy statemen defending their longtime friend, praising her for her 'courage to ask for a safe workplace' and 'to stand up for herself and others.' The women said they were appalled by the 'premeditated and vindictive effort' to 'discredit her voice' In the lengthy complaint Lively also detailed dozens of alleged incidents of sexual harassment and inappropriate behavior toward herself and other women on the set. Among the allegations, The Rhythm Section actress accused Baldoni of being overly concerned with her appearance and weight. She detailed how he allegedly went behind her back to talk to her personal trainer about helping her to lose weight, and disguised a referral to a weight loss expert as someone who would 'help her with probiotics and to combat' strep throat. Baldoni has denied the allegations, however, the damning charges have resulted in his being dropped by talent agency WME, which also represents Lively . Blake Lively Justin Baldoni Share or comment on this article: Blake Lively is defended by director Paul Feig amid allegations of a smear campaign by Justin Baldoni e-mail 60 shares Add comment
Senators Want Biden To Extend TikTok Ban Deadline—But Unclear If He Legally Can
Stocks closed higher on Wall Street as the market posted its fifth straight gain and the Dow Jones notched another record high. The S&P 500 rose 0.3 per cent. The benchmark index’s 1.7 per cent gain for the week erased most of its loss from last week. Wall Street has steadied after a volatile few weeks. Credit: AP The Dow rose 1 per cent as it nudged past its most recent high set last week, and the Nasdaq composite rose 0.2 per cent. The Australian sharemarket is set to climb, with futures pointing to a rise of 52 points, or 0.6 per cent. Markets have been volatile over the last few weeks, losing ground in the runup to elections in November, then surging following Donald Trump’s victory, before falling again. The S&P 500 has been steadily rising throughout this week to within close range of its record. It’s now within about 0.5 per cent of its all-time high set last week. “Overall, market behaviour has normalised following an intense few weeks,” said Mark Hackett, chief of investment research at Nationwide, in a statement. Several retailers jumped after giving Wall Street encouraging financial updates. Gap soared 12.8 per cent after handily beating analysts’ third-quarter earnings and revenue expectations, while raising its own revenue forecast for the year. Discount retailer Ross Stores rose 2.2 per cent after raising its earnings forecast for the year. EchoStar fell 2.8 per cent after DirecTV called off its purchase of that company’s Dish Network unit. Smaller company stocks had some of the biggest gains. The Russell 2000 index rose 1.8 per cent. A majority of stocks in the S&P 500 gained ground, but those gains were kept in check by slumps for several big technology companies. Nvidia fell 3.2 per cent. Its pricey valuation makes it among the heaviest influences on whether the broader market gains or loses ground. The company has grown into a nearly $US3.6 trillion ($5.5 trillion) behemoth because of demand for its chips used in artificial-intelligence technology. Intuit, which makes TurboTax and other accounting software, fell 5.7 per cent. It gave investors a quarterly earnings forecast that fell short of analysts’ expectations. Facebook owner Meta Platforms fell 0.7 per cent following a decision by the Supreme Court to allow a multibillion-dollar class action investors’ lawsuit to proceed against the company. It stems from the privacy scandal involving the Cambridge Analytica political consulting firm. All told, the S&P 500 rose 20.63 points to 5,969.34. The Dow climbed 426.16 points to 44,296.51, and the Nasdaq picked up 42.65 points to close at 2,406.67. European markets closed mostly higher and Asian markets ended mixed. Crude oil prices rose. Treasury yields held relatively steady in the bond market. The yield on the 10-year Treasury fell to 4.41 per cent from 4.42 per cent late Thursday. In the crypto market, bitcoin hovered around $US99,000, according to CoinDesk. It has more than doubled this year and first surpassed the $US99,000 level on Thursday. Retailers remained a big focus for investors this week amid close scrutiny on consumer spending habits headed into the holiday shopping season. Walmart, the nation’s largest retailer, reported a quarter of strong sales and gave investors an encouraging financial forecast. Target, though, reported weaker earnings than analysts’ expected and its forecast disappointed Wall Street. Consumer spending has fueled economic growth, despite a persistent squeeze from inflation and high borrowing costs. Inflation has been easing and the Federal Reserve has started trimming its benchmark interest rates. That is likely to help relieve pressure on consumers, but any major shift in spending could prompt the Fed to reassess its path ahead on interest rates. Also, any big reversals on the rate of inflation could curtail spending. Consumer sentiment remains strong, according to the University of Michigan’s consumer sentiment index. It revised its latest figure for November to 71.8 from an initial reading of 73 earlier this month, though economists expected a slight increase. It’s still up from 70.5 in October. The survey also showed that consumers’ inflation expectations for the year ahead fell slightly to 2.6 per cent, which is the lowest reading since December of 2020. Wall Street will get another update on how consumers feel when the business group The Conference Board releases its monthly consumer confidence survey on Tuesday. A key inflation update will come on Wednesday when the US releases its October personal consumption expenditures index. The PCE is the Fed’s preferred measure of inflation and this will be the last PCE reading prior to the central bank’s meeting in December. AP The Market Recap newsletter is a wrap of the day’s trading. Get it each we e kday afternoon .